> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Xenon Puts Psychiatry Development To The Test With December Depression Results
- URL: https://www.bullished.co/xenon-puts-psychiatry-development-to-the-test-with-december-depression-results-1e803e8b/
- Published: 2026-11-09T22:55:50.000Z
- Updated: 2026-11-09T22:55:50.000Z
- Description: A voluntary enrollment pause makes safety findings central to the next decision on azetukalner.
- Author: Matteo Parrino
- Tags: Earnings, XENE, Industry: Healthcare

[Xenon Pharmaceuticals](https://www.bullished.co/tag/xene/), which develops drugs for neurological and psychiatric disorders, will base further psychiatry development on depression-trial results now expected in December 2026, rather than the first quarter of 2027\. President and Chief Executive Officer Ian Mortimer laid out that conditional path on the company's earnings call Monday, following a voluntary pause in new patient enrollment in September.

## December Sets Up The Decision

A JPMorgan analyst asked how much priority Xenon gives psychiatry alongside its epilepsy work—and what results would justify moving ahead. Mortimer drew a distinction between the evidence supporting the two programs: in psychiatry, "we just know less, right?"

Xenon has the financial resources and development capabilities to continue if azetukalner produces a compelling balance of benefits and risks, Mortimer said. But he also set out the alternative: "if the data don't support future development, then we'll cross that bridge when we get there."

The late-stage depression study has randomized approximately 360 patients. Chief Medical Officer Dr. Chris Kenney said the team brought the expected results forward by removing unnecessary steps from its timetable.

## Safety Shares The Spotlight

The decision will reach beyond whether the drug improves depression scores. Mortimer said the initial results should provide enough information to assess its overall benefits and risks, including its effects on anhedonia—the inability to experience pleasure—and its safety findings.

The trial's main goal measures depression on the Hamilton Depression Rating Scale at six weeks. Kenney said its design provides 90% statistical power to detect an approximately 2.5-point difference from placebo, a difference he described as clinically meaningful.

Safety became a central concern in September, when Xenon voluntarily paused new enrollment after consulting its independent safety-monitoring board about neuropsychiatric adverse events in its depression and bipolar depression studies. Kenney described those events as mostly mild or moderate.

Kenney said their number and severity were consistent with azetukalner's known profile and more than 1,500 patient-years of exposure in epilepsy. However, those events had not appeared in Xenon's earlier mid-stage depression study. He said the FDA had supported the steps the company had taken during its interactions since September.

## Epilepsy Moves Toward Potential Launch

Azetukalner is Xenon's main investigational drug, with development spanning epilepsy, major depressive disorder and bipolar depression. The company also has earlier-stage work in pain and Dravet syndrome, a form of epilepsy.

The epilepsy program is further along: Xenon [submitted its application](https://www.globenewswire.com/news-release/2026/11/09/3398912/33485/en/xenon-reports-q3-2026-financial-results-and-provides-business-update.html?ref=bullished.co) for FDA approval to treat focal seizures in September 2026, according to its results release. Management continues preparing for a potential U.S. launch.

Chief Financial Officer Tucker Kelly said Xenon entered the third quarter with [$1.2 billion](https://finance.yahoo.com/healthcare/articles/xenon-reports-q3-2026-financial-210100330.html?ref=bullished.co) in cash, cash equivalents and marketable securities. Under current operating plans, he said, that would fund operations into 2029 and support launch preparations and drug-development programs. Mortimer's psychiatry decision therefore rests on the clinical evidence, even with resources available to proceed.

Kenney said Xenon plans to take the depression results and its proposed next steps to the safety-monitoring board, then discuss the psychiatry development plan with the FDA.

Learn

- [How To Read An Earnings Call Transcript: Start With Guidance, Then Find What's Missing →](https://www.bullished.co/learn/how-to-read-an-earnings-call/)  
How to read an earnings call transcript: check guidance first, look for dropped metrics, compare growth with last quarter, and watch hedged wording.

### Sources

- [Xenon Reports Q3 2026 Financial Results and Provides Business Update](https://finance.yahoo.com/healthcare/articles/xenon-reports-q3-2026-financial-210100330.html?ref=bullished.co) — Yahoo Finance
- [Xenon Pharmaceuticals: Q3 Earnings Snapshot | wusa9.com](https://www.wusa9.com/article/syndication/associatedpress/xenon-pharmaceuticals-q3-earnings-snapshot/616-e6385b79-c313-4766-b80a-d6924449dbc2?ref=bullished.co) — Associated Press
- [Xenon Pharma GAAP EPS of -$1.11 beats by $0.03 (XENE:NASDAQ) | Seeking Alpha](https://seekingalpha.com/news/4669318-xenon-pharma-gaap-eps-of-1%5F11-beats-by-0%5F03?ref=bullished.co) — seekingalpha.com
- [Xenon Reports Q3 2026 Financial Results and Provides](https://www.globenewswire.com/news-release/2026/11/09/3398912/33485/en/xenon-reports-q3-2026-financial-results-and-provides-business-update.html?ref=bullished.co) — globenewswire.com

### More on Xenon Pharmaceuticals

- [Xenon's Loss Widens To $110.4 Million As Azetukalner Trials And Launch Preparations Cost More](https://www.bullished.co/xenons-loss-widens-to-110-4-million-as-azetukalner-trials-and-launch-preparations-cost-a141b2a2/)
- [T. Rowe Price Investment Management Reports 8.2% Position In Xenon Without Seeking Control](https://www.bullished.co/t-rowe-price-investment-management-reports-8-2-position-in-xenon-without-seeking-control-2af5f6b0/)

[All Xenon Pharmaceuticals (XENE) coverage →](https://www.bullished.co/tag/xene/)